A LINK BETWEEN GUT MICROBIOTA AND ALZHEIMER’S DISEASE: IMPACT OF POLENOPLASMIN
Major Gheorghe Giurgiu1, Prof Dr Med Manole Cojocaru2, SciRes I, EuSpLM
1Deniplant-Aide Sante Medical Center, Biomedicine, Bucharest, Romania
deniplant@gmail.com; Telephone: +4 0744 827 881
https://orcid.org/0000-0002-5449-2712
2Academy of Romanian Scientists
2Titu Maiorescu University, Faculty of Medicine, Bucharest, Romania
cojocaru.manole@gmail.com; Telephone: +4 0723 326 663
https://orcid.org/0000-0002-7192-7490
Alzheimer’s disease is a most common neurodegenerative disorder, which associates with impaired cognition.
Gut microbiota can modulate host brain function and behavior via microbiota-gut-brain axis, including cognitive behavior.
Antibioticscan induce alterations of gut microbiota and gut physiology and also host cognitive behavior, increasing or decreasing risks of Alzheimer’s disease.
The increased permeability of intestine and blood-brain barrier induced by gut microbiota disturbance will increase the incidence of neurodegeneration disorders.
Imbalances in the gut microbiota can be also associated with the neurodegeneration.
There is increasing interest in the role of the peripheral immune system in Alzheimer’s disease pathology.
We are currently assessing whether indoles can also stimulate formation of neurons in Alzheimer’s disease
Disturbances along the brain-gut-microbiota axis may significantly contribute to the pathogenesis of neurodegenerative disorders.
Alterations in the gut microbiota composition induce increased permeability of the gut barrier and immune activation leading to systemic inflammation, which in turn may impair the blood-brain barrier and promote neuroinflammation, neural injury, and ultimately neurodegeneration.
Nutrition is known to play an important role in the pathogenesis of Alzheimer’s disease. In addition, the use of nutraceuticals can be part of a comprehensive approach to delay neurodegeneration.
Objective
Modification of the gut microbiota composition by nutraceuticals may create new preventive and therapeutic options in Alzheimer’s disease.
To arrive at these observations, the authors examined how Polenoplasmin and diet delay neurodegeneration.
Materials and methods
Alzheimer’s disease may begin in the gut, and is closely related to the imbalance of gut microbiota.
We are currently assessing whether indoles can also stimulate formation of neurons in Alzheimer’s disease.

Gheorghe Giurgiu created the product Polenoplasmin under the license of the Deniplant brand owner Gheorghe Giurgiu.
Polenoplasmin acts as a modulator of the gut microbiome in in Alzheimer’s disease.
Polenoplasminfor Alzheimer’s disease.
Polenoplasmin is a nutraceutical (food with a dual role of nutrition and health) for nerve regeneration.
Polenoplasmin for veterinary use being a food, it is not medically certified, but its components have scientifically proven healing qualities.
It contains freeze-dried pollen from Deniplant plants, carob seed powder, brewer’s yeast.
These findings bring us closer to the possibility of novel treatment options to slow down memory loss, which is a common problem with aging and neurodegenerative diseases including but not limited to Alzheimer’s disease.
These include drugs to mimic the action of indoles to stimulate the production of new neurons in the hippocampus or to replace neurons damaged by Alzheimer’s disease, as well as designing dietary intervention using food products enriched with indoles as a preventive measure to slow down aging.
Results
It has now been shown that microbiota affects brain functions through various metabolites with potentially positive or, conversely, toxic properties.
The immune system has a prominent role in Alzheimer’s disease pathogenesis with both innate and adaptive immunity in the central nervous system.
Modulation of gut microbiota through personalized diet or beneficial microbiota intervention will probably become a new treatment for Alzheimer’s disease.
There is a strong link between Alzheimer’s disease and chronic inflammation.
Alzheimer’s disease is a neurodegenerative disorder characterized by a progressive decline in memory and thinking severe enough to interfere with daily life.
Alzheimer’s disease may begin in the gut, and is closely related to the imbalance of gut microbiota.
Modification of the gut microbiota composition by nutraceuticals may create new preventive and therapeutic options in Alzheimer’s disease.
Existing evidence suggests that dietary lifestyle changes may affect cognitive function.
Conclusion
The work reported in this paper addresses the formation of neurons in the brain.
We are currently assessing whether indoles can also stimulate early formation of neurons during brain development.
Another area of potential intervention interest is in situations of Alzheimer’s disease where there is an urgent need to generate new neurons.
This study with Polenoplasmin is another intriguing piece of the puzzle highlighting the importance of lifestyle factors and diet.
References
Hu X, Wang T, Jin F. Alzheimer’s disease and gut microbiota. Sci. China Life Sci. 2016, 59, 1006-23.
Jiang C, Li G, Huang P, Liu Z, Zhao B.The Gut Microbiota and Alzheimer’s Disease.J Alzheimers Dis. 2017;58(1):1-15.
Szablewski L.Human Gut Microbiota in Health and Alzheimer’s Disease.J Alzheimers Dis. 2018;62(2):549-60.
Kesika P, Suganthy N, Sivamaruthi BS, Chaiyasut C.Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer’s disease.Life Sci. 2021;264:118627.
Angelucci F, Cechova K, Amlerova J, Hort J.Antibiotics, gut microbiota, and Alzheimer’s disease.J Neuroinflammation. 2019;16(1):108.
Varesi A, Pierella E, Romeo M, et al. The Potential Role of Gut Microbiota in Alzheimer’s Disease: From Diagnosis to Treatment.Nutrients. 2022;14(3):668.